GLUC Glucose Health, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1420108 · Fiscal year ends 12/31
Financial factors as of 2017-09-30 (2017Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.6%
TTM net income YoY73.8%
TTM EPS YoY—
Revenue 3-yr CAGR237.6%
Net income 3-yr CAGR—
Margins
Gross margin65.4%
Operating margin-36.8%
Net margin-96.5%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-241.9%
ROIC (approx.)—
Asset turnover2.51x
Leverage & solvency
Liabilities / assets1,717.4%
Debt / equity—
Current ratio0.06x
Interest coverage-0.29x
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-192.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2017Q32017-09-30 | 2017Q22017-06-30 | 2017Q12017-03-31 | 2016Q4*2016-12-31 | 2016Q32016-09-30 | 2016Q22016-06-30 | 2016Q12016-03-31 | 2015Q4*2015-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $23,783 | $34,046 | $15,111 | $15,190 | $2,110 | $295,809 | $120 | $1,640 |
| Cost of revenue | $790 | $272 | $14,638 | $14,804 | $4,734 | $274,464 | $60 | $1,585 |
| Gross profit | $22,993 | $33,774 | $473 | $386 | -$2,624 | $21,345 | $60 | $55 |
| SG&A expense | $4,694 | $7,557 | $12,490 | $6,798 | $36,356 | $5,767 | $2,917 | $79,222 |
| Operating income | $4,635 | $16,077 | -$28,313 | -$24,848 | -$55,556 | $6,032 | -$12,275 | -$14,913 |
| Interest expense | $5,720 | $5,096 | $696 | $99,232 | $105,263 | $93,402 | $16,988 | $21,449 |
| Pretax income | $18,769 | $49,258 | -$29,009 | -$124,080 | -$160,819 | -$87,370 | -$29,263 | -$46,798 |
| Net income | $18,769 | $49,258 | -$29,009 | -$124,080 | -$160,819 | -$87,370 | -$29,263 | -$46,798 |
| EPS (basic) | 0.00 | 0.01 | -0.01 | — | -0.06 | -0.03 | -0.01 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16,636 | $18,313 | $9,008 | $20,542 | $23,639 | $27,773 | $1,946 | $2,055 |
| Receivables | $9,105 | $8,795 | $9,632 | $11,724 | $11,742 | $168,346 | $3,150 | $3,150 |
| Inventory | $0 | $0 | $0 | — | $6,418 | $8,310 | $8,310 | $8,370 |
| Current assets | $26,158 | $27,108 | $18,640 | $32,905 | $43,662 | $206,809 | $51,332 | $15,107 |
| Total assets | $26,353 | $27,318 | $18,865 | $33,145 | $43,962 | $207,109 | $51,632 | $15,407 |
| Current liabilities | $452,585 | $476,607 | $542,431 | $528,592 | $417,594 | $423,804 | $454,763 | $403,226 |
| Total liabilities | $452,585 | $476,607 | $542,431 | $528,592 | $417,594 | $423,804 | $454,763 | $403,226 |
| Shareholders' equity | -$426,232 | -$449,289 | -$523,566 | -$495,447 | -$373,632 | -$216,695 | -$403,131 | -$387,819 |
| Shares outstanding | 4.52M | 3.98M | 3.42M | 3.31M | 3.03M | 2.75M | 2.54M | 2.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1,677 | -$695 | -$11,534 | -$3,347 | $61,866 | -$49,173 | -$48,609 | -$9,239 |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | — | — | $0 | -$66,000 | $75,000 | $48,500 | $2,500 |
| Stock-based compensation | — | — | — | $0 | $1,875 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.